Table 1 Baseline characteristics of LR-MDS patients in the two cohorts.
Demographic | Learning cohort (n = 97) | Validation cohort (n = 54) | p |
|---|---|---|---|
Median age (years) | 75 (41–92) | 75 (30–90) | |
Male %(n) | 62,8 (61) | 59 (32) | |
Female %(n) | 37,2 (36) | 41 (22) | |
Hematological | Mean (range) | Mean (range) | p |
Hb g/dL | 9,67 (7,1–12,5) | 9,69 (7–12,7)) | |
Rec# (x1012/L) | 0,088 (0,004–2,68) | 0,053 (0,33–0,01) | |
sEPO mU/mL | 235,22 (7,2–2010) (n = 90) | 53 (11–335) (n = 24) | 0.030 |
Iron markers | Mean (range) | Mean (range) | p |
Ferritin ng/mL | 628 (7–7544) | 367 (63–2259) | |
sTFr mg/L | 2,81 (0,51–17) | 2 (1–5,42) | |
Tf % | 54 (7–227) | 38,5 (11–90) | |
RBC transfusion burden | %(n) | %(n) n = 48 | p |
TD %(n) | 8,7 (9) | 6,25 (3) | |
RBC U/8 weeks median (range) | 2 (0–4) | 2 (0–4) | |
WHO 2022 | %(n) n = 83 | %(n) n = 44 | p |
MDS-LB | 40,9 (34) | 34,1 (15) | |
MDS-SF3B1 | 39,8 (33) | 38,6 (17) | |
MDS-LB RS | 6 (5) | 2,3 (1) | |
MDS del(5)q | 7,3 (6) | 9,1 (4) | |
MDS-IB1 | 6 (5) | 15,9 (7) | |
IPSS-R Category | %(n) n = 97 | %(n) n = 54 | p |
Very low | 20,7 (20) | 33 (18) | |
Low | 68 (66) | 59 (32) | |
Intermediate | 11,3 (11) | 8 (4) | |
IPSS-M Category | %(n) n = 83 | %(n) n = 44 | p |
Very low | 18,3 (15) | 15,9 (7) | |
Low | 46,9 (39) | 54,6 (24) | |
Moderate low | 10,8 (9) | 13,6 (6) | |
Moderate high | 12 (10) | 6,8 (3) | |
High | 9,6 (8) | 6,8 (3) | |
Very high | 2,4 (2) | 2,3 (1) | |
HI-E (IWG 2018) | %(n) | %(n) | p |
Non-responders | 46,6 (48) | 45 (23) | |
Short responders (≤24 months) | 25,2 (26) | 28 (16) | |
Long responders (>24 months) | 28,1 (29) | 27 (15) | |
Median DOR (months) | 23 (10–78) | 18 (6–56) | 0.02 |
